RHY · ASX

Rhythm Biosciences Limited (ASX:RHY)

AU$0.062

 -0.001 (-1.587%)
ASX:Live
09/05/2025 02:47:15 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RHY Overview

RHY Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RHY

Website

Rhythm Biosciences Limited

Telephone

61.3.9614.0600

Address

30 Flemington Road Bio21 Institute Parkville, Victoria (VIC) 3010

Description

Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. It offers a diagnostic blood test for screening for colorectal cancer under the ColoSTAT brand. The company was founded on June 1, 2017, and is headquartered in Parkville, Australia.

RHY Price Chart

Key Stats

Market Cap

AU$17.39M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.14

Trade Value (12mth)

AU$5,460.00

1 week

-3.08%

1 month

-10%

YTD

-27.59%

1 year

-21.25%

All time high

2.04

Key Fundamentals

EPS 3 yr Growth

-13.80%

EBITDA Margin

N/A

Operating Cashflow

-$6m

Free Cash Flow Return

-179.80%

ROIC

-200.90%

Interest Coverage

-2,671.80

Quick Ratio

1.60

Other Data

Shares on Issue (Fully Dilluted)

256m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RHY Announcements

Latest Announcements

Date Announcements

02 May 25

Notification regarding unquoted securities - RHY

×

Notification regarding unquoted securities - RHY

01 May 25

Proposed issue of securities - RHY

×

Proposed issue of securities - RHY

24 April 25

Quarterly Activities Report and Appendix 4C 31 March 2025

×

Quarterly Activities Report and Appendix 4C 31 March 2025

14 April 25

RHY ISO13485 Recert Market Update

×

RHY ISO13485 Recert Market Update

11 April 25

Application for quotation of securities - RHY

×

Application for quotation of securities - RHY

08 April 25

Change in substantial holding

×

Change in substantial holding

31 March 25

EGM - Investor Presentation

×

EGM - Investor Presentation

31 March 25

RHY - Results of Meeting

×

RHY - Results of Meeting

19 March 25

RHY Genetype Commercial Sales

×

RHY Genetype Commercial Sales

18 March 25

Appointment of Chief Financial Officer

×

Appointment of Chief Financial Officer

18 March 25

Notification regarding unquoted securities - RHY

×

Notification regarding unquoted securities - RHY

17 March 25

Notification of cessation of securities - RHY

×

Notification of cessation of securities - RHY

05 March 25

RHY Investor Webinar

×

RHY Investor Webinar

27 February 25

Investor Webinar

×

Investor Webinar

27 February 25

RHY - EGM Notice of Meeting and Proxy Form

×

RHY - EGM Notice of Meeting and Proxy Form

21 February 25

Half-Year Financial Report and Appendix 4D

×

Half-Year Financial Report and Appendix 4D

12 February 25

Becoming a substantial holder

×

Becoming a substantial holder

04 February 25

Genetype Commercial Integration Completion

×

Genetype Commercial Integration Completion

23 January 25

Quarterly Activities Report and Appendix 4C - Dec24

×

Quarterly Activities Report and Appendix 4C - Dec24

14 January 25

About the Genetype Acquisition

×

About the Genetype Acquisition

24 December 24

Notification regarding unquoted securities - RHY

×

Notification regarding unquoted securities - RHY

24 December 24

Completion of Genetype Risk Assessment Portfolio Acquisition

×

Completion of Genetype Risk Assessment Portfolio Acquisition

24 December 24

GTG: GTG completes sale of geneType business and assets

×

GTG: GTG completes sale of geneType business and assets

23 December 24

RHY Acquires Genetype Genetic Risk Assessment Business

×

RHY Acquires Genetype Genetic Risk Assessment Business

20 December 24

Pause in Trading

×

Pause in Trading

RHY Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.8 9.5 19.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.02 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.4 19.6 -38.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.7 -7.9 -43.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.03 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.02 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 428.4 -23.1 -91.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 214 222 228 Lock Lock Lock
Basic m Lock Lock Lock Lock 214 222 228 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 11 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.8 -86.6 -4.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -11 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.9 -1.9 26.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -12 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -45.4 -2.6 25.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -11 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -8 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.0 6.5 16.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -7 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 12 4 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 -7 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.2 -8.2 11.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 8 4 1 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 8 8 2 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -4 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 7 6 1 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 7 6 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 336.9 -21.2 -83.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -104.2 -106.8 -451.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -119.3 -139.9 -790.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -243.2 -171.0 -246.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -191.9 -123.3 -200.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -141.8 -104.4 -179.8 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A -2,671.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 0.4 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -100.7 -69.5 -68.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.3 4.0 1.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.3 2.5 1.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.7 58.6 85.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -696.8 -394.1 -1,092.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -104.2 -106.8 -451.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 1.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -119.3 -139.9 -790.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -119.3 -139.9 -790.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 2,666.2 2,541.6 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 2,666.2 2,541.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,585.6 99.5 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,585.6 2,566.7 2,541.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RHY Shortsell

Frequently Asked Questions

The current share price of Rhythm Biosciences Limited (RHY:ASX) is AU$0.062.
The 52-week high share price for Rhythm Biosciences Limited (RHY:ASX) is AU$0.14.
The 52-week low share price for Rhythm Biosciences Limited (RHY:ASX)? is AU$0.04.
Rhythm Biosciences Limited (RHY:ASX) does not pay a dividend.
Rhythm Biosciences Limited (RHY:ASX) does not pay a dividend.
Rhythm Biosciences Limited (RHY:ASX) does not offer franking credits.
Rhythm Biosciences Limited (RHY:ASX) is classified in the Healthcare.
The current P/E ratio for Rhythm Biosciences Limited (RHY:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.